117
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Anticancer activity of Indonesian Melia azedarach L.: Phyto-chemistry, in vitro and in silico studies

, , , , , , , , , , , , , & show all
Pages 12-26 | Received 11 Dec 2022, Accepted 14 Jan 2023, Published online: 28 Mar 2023
 

Abstract

This study describes the isolation of bioactive compounds and their in vitro anticancer activities from Melia azedarach L leaves from Karanglor, Karangan, Karanganom Klaten, Central Java-Indonesia. Isolated and characterised were the phenolics, kaempferol 7-O-rutinoside 1 and 4-methoxyresorcinol 3, The anticancer activity of the crude methanol extract of M. azedarach against a number cell lines (LNCaP, MDA-MB-231, and MCF-7) was found to be moderate; kaempferol derivatives were notable for their antiproliferative activities. Computational analysis, including molecular docking simulations and molecular dynamic studies, were used to investigate the feasibility of radiolabelled versions of 1 and 3 as theranostic agents targeting tyrosine kinase-type cell surface receptor HER2 in cancer - the iodinated derivatives 2 and 4, respectively, were used in this investigation as surrogates. The corresponding radioiodinated 2 and 4 were found to have high binding affinities of 10.1 and 5.7 kcal/mol, respectively, and have a good stability on the receptor.

GRAPHICAL ABSTRACT

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.